

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number
WO 2003/103706 A3

(51) International Patent Classification⁷: **A61K 39/39**,
38/17, A61P 35/00, C07K 14/47, 14/705, C12N 15/63,
15/12, 5/10

(74) Agent: DALTON, Marcus, Jonathan, WI; Glaxo-
SmithKline, CN925.1, 980 Great West Road, Brentford,
Middlesex TW8 9GS (GB).

(21) International Application Number:
PCT/EP2003/006095

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 6 June 2003 (06.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0213364.3 11 June 2002 (11.06.2002) GB
0221689.3 18 September 2002 (18.09.2002) GB

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*): GLAXO-
OSMITHKLINE BIOLOGICALS S.A. [BE/BE]; Rue de
l'Institut 89, B-1330 Rixensart Brussels (BE). GLAXO
GROUP LIMITED [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CASSART,
Jean-Pol [BE/BE]; GlaxoSmithKline Biologicals s.a.,
Rue de l'Institut 89, B-1330 Rixensart Brussels (BE).
GERARD, Catherine, Marie, Ghislaine [BE/BE]; Glaxo-
SmithKline Biologicals s.a., Rue de l'Institut 89, B-1330
Rixensart Brussels (BE). HAMBLIN, Paul, A [GB/GB];
GlaxoSmithKline, Gunnels Wood Road, Stevenage,
Hertfordshire SG1 2NY (GB). PALMANTIER, Remi,
M [FR/BE]; GlaxoSmithKline Biologicals s.a., Rue de
l'Institut 89, B-1330 Rixensart Brussels (BE).

(88) Date of publication of the international search report:
19 February 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMMUNOGENIC COMPOSITIONS COMPRISING A XENOGENIC PROSTATE PROTEIN P501S

(57) **Abstract:** The present invention relates to pharmaceutical/immunogenic compositions and methods for inducing an immune response against tumour-related antigens. More specifically, the invention relates to non-human prostate-specific antigens, more precisely to the non-human prostate-specific P501S, which can be used as xenogeneic antigen in prostate cancer vaccine therapy and as diagnostic agents for prostate tumours in humans, to immunogenic compositions containing them, to methods of manufacture of such compositions and to their use in medicine. Methods for formulating vaccines for immunotherapeutically treating P501S-expressing prostate tumors, prostatic hyperplasia, and prostate intraepithelial neoplasia (PIN) are also provided.

WO 2003/103706 A3